Headline News

 

Novartis remibrutinib significantly reduces relapse rates in Phase III relapsing multiple sclerosis studies

Posted on September 08, 2026

Lilly agrees to buy Merida Biosciences, betting on antibody-targeting approach to autoimmune disease

Posted on September 08, 2026

New year-long data show Taltz and Zepbound combination sustains gains in psoriatic disease and obesity

Posted on September 08, 2026

Sanofi’s MenQuadfi cleared in the EU for infants from six weeks old against invasive meningococcal disease

Posted on September 08, 2026

Novartis del desiran misses primary endpoint in Phase III HARBOR trial for myotonic dystrophy type 1

Posted on September 08, 2026

Novartis pelacarsen misses primary endpoint in Phase III Lp(a)HORIZON cardiovascular trial

Posted on September 07, 2026

AbbVie’s etentamig delivers significant Phase 3 benefit in relapsed or refractory multiple myeloma

Posted on September 07, 2026

Thermo Fisher expands microplate reader portfolio with Multiskan Ease launch

Posted on September 06, 2026

GSK moves mRNA flu vaccine toward phase III after stronger immune responses in Phase II

Posted on September 06, 2026

SANOVO trial supports Tagrisso and Orpathys combination in untreated EGFR mutated lung cancer

Posted on September 05, 2026

AstraZeneca completes global licensing deal for lung cancer therapy Zegfrovy

Posted on September 05, 2026

EU approves Enhertu plus pertuzumab as first new first line HER2 positive metastatic breast cancer regimen in over a decade

Posted on September 04, 2026

FDA approves AstraZeneca’s Etcamah combination for first line advanced HR positive breast cancer

Posted on September 04, 2026

Tagrisso combined with Orpathys shows statistically significant and highly clinically meaningful gains in progression free survival for first line MET overexpressing EGFR mutated lung cancer

Posted on September 01, 2026

AstraZeneca finalizes worldwide licensing agreement for oral EGFR inhibitor Zegfrovy in lung cancer treatment

Posted on September 01, 2026